Part Two, Lilly: A Strategic Game-Theory Analysis of Why the Giant That Can Simply Pay Forces Every Other Player to Move, Across the Three Franchises That Fit at Once, the Finite Windfall Best Converted Into a Permanent Platform, and the Forcing Entry That Turns a Quiet Negotiation Into a Contested Auction.
Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout
About This Series
This is the second of three connected papers imagining how three large pharmaceutical companies, Novartis, then Lilly, then Roche, would approach acquiring Arrowhead Pharmaceuticals, and how Arrowhead would respond. As with the first, this paper is a strategic thought experiment built entirely on the public record: each company’s actual acquisition history, its publicly stated strategy, the way it has behaved in past deals under its current leadership, and the public facts about Arrowhead. It is not a prediction, and not a claim that any deal is under discussion. I have no knowledge of any such discussions. Part One looked at Novartis, the partner that knows Arrowhead from the inside, and ended on a warning: the company that understands the value best is not the company that can most easily afford it. This paper introduces the one that can.
Executive Summary
If Novartis is the suitor that knows Arrowhead’s value, Lilly is the suitor that can least be stopped from paying it. Lilly enters this story transformed by the most powerful financial engine in the industry. Its weight-loss and diabetes franchise, built on Mounjaro and Zepbound, has lifted the company toward revenue in the mid-eighties of billions of dollars a year, growing more than fifty percent in its most recent quarter, and that windfall has funded a deliberate, aggressive campaign to diversify the company beyond obesity through acquisition. Lilly is not shopping with a careful budget. It is shopping with the deepest pockets in the business and a stated intention to use them.
Lilly also fits Arrowhead across more of its franchises than any other suitor. Its obesity empire could absorb Arrowhead’s differentiated, non-GLP-1 weight-loss mechanisms as a complement rather than a competitor. Its committed Alzheimer’s franchise, anchored by an approved amyloid-clearing antibody, gives it a direct strategic reason to want Arrowhead’s complementary tau-lowering, brain-delivery platform. Its appetite for cardiometabolic innovation, already demonstrated by other recent deals, lines up with Arrowhead’s approved cardiometabolic product and pipeline. Where Novartis fits Arrowhead on strategy, Lilly fits it on strategy and can pay without strain.
This paper lays out why Arrowhead fits Lilly, how Lilly has actually behaved as a dealmaker (a historically disciplined buyer that has, on the strength of the obesity windfall, deliberately widened its aperture and become the industry’s most active acquirer), how a rational Lilly would approach Arrowhead, and how Arrowhead would respond to the richest bidder at the table. The chess idea that organizes it is “check”: the move that does not win the game by itself, but forces every other player to respond. Lilly’s entry onto the board is a “check.” From the moment the giant is in the game, neither Novartis nor Roche can proceed as though it were not.
I. The Move That Forces a Response
In the first paper, Novartis heard the warning, “en garde,” the old courtesy that announced an attack on the queen. A warning, though, is not yet a threat. It tells the other players that the queen is in danger without forcing anyone to do anything about it. What turns a warning into action is the arrival of a move that cannot be ignored, and in chess that move has a name everyone knows: “check.” A “check” is the move that attacks the king directly and compels an answer. A player in check cannot pursue his own plans, cannot develop a distant piece, cannot wait. He must respond to the threat in front of him, on this move, before anything else. It does not by itself win the game. What it does is take the initiative away from the opponent and hand it to the player giving check, forcing the whole board to reorganize around a single threat.
Lilly’s entry into the contest for Arrowhead is a “check.” Not because Lilly is guaranteed to win, it is not, but because once a company with Lilly’s resources is plausibly in the game, no other suitor can behave as though it were not there. Novartis’s comfortable plan, to deepen its partnership gradually and acquire on its own timetable, is a plan that assumes the freedom to wait. Lilly removes that freedom. A disciplined buyer can take its time only when no one is about to take the asset away from it, and the arrival of a giant that can pay any plausible price is exactly the event that ends the waiting. This paper is about the player whose mere presence puts the others in check, and about why the richest suitor changes the game for everyone even before it makes an offer.
II. Why Arrowhead Fits Lilly
Lilly fits Arrowhead on more fronts than any other suitor, and the breadth is the point, because it is what justifies a larger number than any single-franchise rationale could. Begin with the franchise that defines Lilly: obesity. Lilly is the dominant force in weight-loss medicine, with a franchise built on the GLP-1 drugs, the class of injections, sold as Mounjaro and Zepbound, that have reshaped the industry. Arrowhead’s obesity programs do not compete with that franchise; they complement it. They work through mechanisms entirely different from the GLP-1 drugs, aimed at the quality of weight lost, the preservation of muscle, the reduction of visceral and liver fat, the kinds of improvements that the next phase of obesity medicine will be judged on. A company that already leads in obesity has the most to gain from owning the differentiated mechanisms that extend the franchise into its next era, and the most to lose from letting a competitor own them instead.
The Alzheimer’s fit is just as direct, and it is documented. Lilly is committed to neurodegeneration; it won approval for its Alzheimer’s antibody Kisunla, known generically as donanemab, and has launched it globally. That commitment is exactly what makes Arrowhead’s central nervous system platform valuable to Lilly, because Kisunla works by clearing amyloid, one of the two toxic proteins that build up in the Alzheimer’s brain, while Arrowhead’s approach lowers tau, the other principal driver of the disease, using a delivery technology Lilly does not possess. A company already selling an Alzheimer’s drug, already carrying the commercial and medical infrastructure for the disease, is the natural home for a complementary tau program delivered by a platform it would otherwise have to build from scratch.
The cardiometabolic fit completes the picture. Lilly’s recent dealmaking shows a clear appetite for cardiometabolic innovation beyond its weight-loss drugs, including approaches that aim to treat with durable, infrequent dosing. Its acquisition of Verve Therapeutics, a gene-editing company pursuing a one-and-done approach to cardiovascular risk, is the clearest signal of that appetite. Verve’s programs are still in development rather than on the market, which is precisely the point: Lilly was willing to buy the capability years ahead of any approved product, because the strategic logic of durable, infrequent cardiometabolic therapy was compelling enough on its own. Arrowhead’s approved cardiometabolic product and the pipeline behind it speak to exactly the same appetite, with the added advantage of being further along. Taken together, the fit spans obesity, neurodegeneration, and cardiometabolic disease at once. Arrowhead is not a single-franchise bet for Lilly. It is three strategic fits in one company, and a buyer evaluating three fits at once can justify a price that no single fit would support.
Even three fits understates it, because the three visible franchises are only what the platform produces today. Arrowhead’s delivery system reaches across the liver, muscle, lung, fat tissue, and the central nervous system in the clinic, and it has already extended to two more, an ocular program for glaucoma with non-human primate proof of mechanism and an early heart-muscle program, with more tissues to follow. It will keep generating programs in those tissues and others for years. An acquirer is buying not three franchises but the exclusive right to that entire future output, much of which will land in therapeutic areas beyond the three that fit Lilly now. For most acquirers that open-ended reach is a mixed blessing, because a platform that keeps producing drugs in unfamiliar areas forces a choice each time, build a presence in that area or license the program away, and not every buyer wants to be pulled into territory it does not already occupy. Here Lilly is the exception, and this is the heart of why Arrowhead fits Lilly better than it fits a more focused buyer. Lilly’s entire stated strategy is to broaden, to use its windfall to become a wide innovation engine across many therapeutic areas rather than a single-franchise giant. A platform whose output sprawls across tissues is not a burden to a company that wants to sprawl; it is fuel. Where a disciplined, focused acquirer would see the platform’s open-ended reach as a series of awkward obligations, Lilly sees the raw material of exactly the diversified company it has already announced it intends to become. The multi-tissue engine that complicates the calculus for everyone else is, for Lilly, a feature aligned with its deepest strategic goal.
III. The Cliff Lilly Is Not Facing, and the One It Is Front-Running
Lilly’s relationship to the patent cliff is different from Novartis’s, and the difference matters, because it changes why Lilly buys. Novartis acquires to replace revenue it is about to lose. Lilly is not in that position. Far from staring at a cliff, Lilly is enjoying the steepest upward climb in the industry, its obesity and diabetes franchise driving revenue growth of more than fifty percent in its most recent quarter and full-year revenue guided well into the eighties of billions of dollars. Lilly does not need to buy Arrowhead to plug a hole, because there is no hole. It buys from strength, not from need.
That distinction is worth stating plainly, because it would be easy and wrong to lump all three suitors into a single cliff-driven story. Lilly’s motivation is not desperation; it is diversification. A company whose fortunes are concentrated in a single therapeutic area, however spectacularly successful, carries a concentration risk, and Lilly’s leadership has been explicit about wanting to broaden the company into a wider innovation engine rather than remain a one-franchise giant. The acquisitions it has made across oncology, immunology, neuroscience, and cardiometabolic disease are the visible expression of that intent, and the growth of those newer areas, rising sharply as a share of the company’s key-product revenue, shows the diversification is real and deliberate.
There is a cliff in Lilly’s future, even so, and the company is wise enough to be front-running it. Every blockbuster eventually faces competition and the loss of exclusivity, and a franchise as large as Lilly’s obesity business will one day face both. Buying now, while the windfall is at its peak, lets Lilly diversify from a position of overwhelming strength rather than scrambling later from weakness. Lilly’s acquisitiveness is therefore not cliff-replacement in the way Novartis’s is; it is cliff-prevention. For Arrowhead, the implication is what matters: Lilly is the one suitor whose interest does not depend on a deadline, which means it can move whenever it chooses, including early, and can pay a price that reflects the asset’s full value rather than one disciplined by the urgency of a closing window.
IV. How Lilly Actually Does Deals
Lilly’s dealmaking style has changed, and understanding the change is the key to understanding how it would approach Arrowhead. Historically, Lilly was a disciplined and relatively cautious acquirer. Its largest acquisition for many years was a roughly $8 billion purchase of an oncology company, and most of its deals were smaller and earlier-stage. By the standards of its largest peers, Lilly was not a big-game hunter. It focused on early science and bolted on selectively, and its average deal was modest.
The obesity windfall changed the company’s posture deliberately and visibly. Lilly’s leadership widened the aperture, sharpened its business development function, and turned the company into the industry’s most active dealmaker. In a single recent stretch it announced a rapid series of acquisitions across multiple therapeutic areas, committing many billions of dollars upfront and far more in total potential value, an intensity of dealmaking that would have been out of character only a few years earlier. The strategy was stated openly: to use the windfall to become a backbone of the broader innovation ecosystem, not merely a single-franchise leader. The honest reading of Lilly’s style, then, is that its old discipline was never really about reluctance to pay; it was about capital. Lilly was disciplined because it had to be. The windfall removed the constraint, and the behavior changed accordingly.
This is the crucial analytical point about Lilly as a suitor, and it distinguishes Lilly sharply from Novartis. Novartis stretches beyond its stated discipline only for assets at the dead center of its strategy, and even then it frames the stretch as exceptional. Lilly has simply raised its whole ceiling. A company that has chosen to deploy its windfall aggressively across many areas, and that fits Arrowhead on three franchises at once, is a company for which a large acquisition is not an exception to the strategy but an expression of it. The platform’s tendency to generate programs across many tissues, awkward for a focused buyer, is the same tendency that serves Lilly’s announced ambition to broaden, which means Lilly can value the open-ended future of the platform more comfortably than a more disciplined rival can. Where Novartis would have to talk itself into a number, Lilly has already decided, as a matter of policy, that large numbers are how it intends to grow.
V. The Lilly Playbook for Arrowhead
Put the breadth of fit, the absence of a deadline, and the deep pockets together, and Lilly’s characteristic approach to Arrowhead takes shape. It is the approach of a buyer who can afford the asset, wants it for several reasons at once, and is not forced by any clock to hurry, which is a genuinely powerful combination, and a different kind of threat from Novartis’s.
Lilly’s central advantage is the simplest and the hardest to counter: it can pay. The price that would force a disciplined buyer to hesitate is, for Lilly, comfortably within reach, which means Lilly can win this contest on the one dimension where being a price-taker hurts the other suitors most. A buyer that can comfortably absorb the full value of the asset does not need clever tactics to suppress the price; it can simply meet the price and rely on its rivals’ inability to follow. That is the purest form of the “check”: a threat the others cannot match on the merits, only respond to.
The numbers behind that advantage are worth stating, because they are what set the ceiling for everyone else. Lilly's market value has lately ranged from roughly $900 billion to above $1 trillion, its balance sheet carries modest net debt against rapidly growing cash generation, and it can use its richly valued stock as acquisition currency in a way no rival can match. The scale of that advantage is easy to miss: even a $150 billion acquisition would amount to only about a sixth of Lilly's market value, financeable through a blend of debt and stock with far less strain than the same price would impose on any competitor. Working from its own filings, Lilly is therefore comfortable across essentially the entire range a sale of Arrowhead would plausibly occupy, to roughly $150 billion, on the order of $970 a share, a price that would strain its rivals but that Lilly can absorb with room to spare, and its premium-valued equity provides a further lever well beyond that, toward $200 billion or more. These are estimates drawn from public filings, not precise figures, but they make the central point unmistakable: for Lilly, the binding constraint is never whether it can afford Arrowhead. It is only whether it judges the asset worth winning. That is precisely why Lilly sets the ceiling of the contest, and why the prospect of Lilly setting it pressures every other participant to act.
The timing question for Lilly is more interesting than for the others, precisely because Lilly has the luxury of choosing. A buyer with a deadline acts when the deadline demands. A buyer without one acts when the strategic logic is best, and for Lilly the strategic logic argues for moving early rather than late. Arrowhead’s value is poised to jump sharply when its central nervous system program reads out, and a buyer that intends to pay full value anyway has a reason to act before that jump rather than after, capturing the platform while the price still reflects uncertainty the buyer is willing to bear. Lilly is uniquely able to take that risk, because it can absorb a disappointing readout more easily than a smaller, more concentrated buyer could. The deep-pocketed, diversified giant is precisely the player best positioned to buy before the proof, which makes Lilly not only the suitor that can pay the most, but potentially the suitor that moves the soonest.
Underneath the question of whether Lilly can pay sits a larger one of whether Lilly should, and here the answer is not merely yes but emphatically so. Lilly is not a company trying to survive a hard decade; it is a company having the best decade in its history, and the deepest question facing any business at such a height is whether the height will last. The windfall is enormous, but it is also, by Lilly’s own admission, finite: the franchise generating most of its revenue today will eventually face its own competition and its own loss of exclusivity. Windfalls fade, and the companies that turn a golden moment into permanent stature are the ones that spend the moment’s resources on something the moment itself cannot provide. For Lilly, Arrowhead is that something, a self-renewing platform whose value keeps compounding long after the obesity wave that paid for it has crested. If the platform delivers, and that condition governs everything in this series, a record price would not be an extravagance; it would be the single highest-return use of money that will not keep coming forever. The want here is not for another franchise to add to a crowded desk. It is for the one asset that converts a spectacular but finite run into lasting institutional dominance.
That dominance is not only a matter of scale; it is a matter of identity. Acquiring Arrowhead would not merely diversify Lilly; it would help define what Lilly becomes. The company that already reset the treatment of obesity could enter the 2030s as the company that also owns the most productive genetic-medicine engine in the industry, extending its reach from metabolic disease into the brain, the muscle, and tissue after tissue beyond. That engine is more than a delivery platform; it sits on a proprietary dataset that, fed into Arrowhead’s own AI-driven design, makes each new program faster and surer than the last. A separate analysis in this body of work argues that no newcomer can rebuild that advantage, because AI models are available to everyone while the data that makes them useful is available to no one else, and the edge only widens the longer the platform runs. That is the difference between being the dominant company of a single era and being the company that carries its dominance into the next one. For the most ambitious organization in the industry, holding more capital to deploy than any rival, that is precisely the prize the ambition was built for, and if the platform delivers, the kind of acquisition a company is remembered for making.
The honest qualification is that breadth of fit can also dilute urgency. A company spending aggressively across many therapeutic areas at once has many priorities competing for attention and capital, and Arrowhead, however good a fit, is one opportunity among many on Lilly’s desk. The same diversification strategy that makes Arrowhead attractive to Lilly also means Lilly is not depending on Arrowhead the way a more focused buyer might. A giant with many options can pay for any one of them; it can also walk away from any one of them, because none is essential. Lilly’s strength, the breadth that lets it pay, is also the reason its desire may be wide rather than deep.
VI. What Lilly’s Entry Does to the Others
The most important effect of Lilly is not what it does to Arrowhead but what it does to the other suitors, because this is where the “check” reorganizes the whole board. Recall Novartis’s position from the first paper: the informed partner, content to move on its own disciplined timetable, confident that its inside knowledge gave it an advantage. That confidence depended on a quiet board. The moment Lilly is plausibly in the game, Novartis’s patience becomes a danger rather than a virtue, because the thing Novartis cannot afford is to wait politely while a buyer it cannot outspend takes the asset away. The “check” forces Novartis to choose: move now, ahead of its preferred timetable and possibly above its preferred price, or risk losing Arrowhead entirely to a richer rival. Either way, Lilly has taken the initiative away from Novartis without making a single offer.
The same logic will fall, in the next paper, on Roche. For now it is enough to see the structure. A single disciplined suitor can dictate the pace of a negotiation, because it is the only buyer in the room. Two suitors cannot, because each must now act with one eye on the other, and the more powerful of the two sets the tempo. Lilly’s deep pockets do not merely make Lilly a strong bidder; they convert the entire situation from a patient bilateral negotiation, in which Arrowhead deals with one suitor at a time, into a contested one, in which every suitor must move faster and offer more for fear of being outbid. That conversion, from a calm negotiation into a contested race, is the single most valuable thing that can happen to a company being courted, and it is Lilly’s mere presence that triggers it.
This is why the giant matters even if the giant never wins. A “check” does not have to lead to checkmate to change the game; it only has to force a response. Whether Lilly ultimately acquires Arrowhead or not, its plausible interest is enough to put Novartis, and soon Roche, in a position where waiting is no longer safe. The suitors are no longer deciding whether to pursue Arrowhead on their own schedules. They are deciding how to respond to each other, which is exactly the condition under which a target stops being a price-taker and starts setting the terms.
VII. How Arrowhead Plays It
From Arrowhead’s side of the table, the arrival of a suitor like Lilly is, in the plainest terms, good news, and the leverage analysis is the most straightforward of the three papers. The richest bidder is in some ways the easiest counterpart for a confident seller, because the price that satisfies Arrowhead is the price Lilly can most easily pay. There is no need to talk a reluctant buyer into a number it cannot reach. The number Arrowhead believes its platform is worth is a number comfortably within Lilly’s means, which removes the most common obstacle in a large acquisition, the gap between what the seller wants and what the buyer can bear.
Arrowhead’s deeper advantage, developed throughout this series, is that it does not need to sell at all, and Lilly’s presence makes that advantage more valuable rather than less. A company that can credibly continue alone, and that now has a demonstrably willing and able acquirer, holds the strongest possible position: it can decline anything short of full value, knowing that a buyer exists who can meet full value, and knowing that the existence of that buyer pressures the other suitors to do the same. Arrowhead does not have to choose Lilly. It only has to let Lilly’s presence remind every other suitor that the price floor has risen. The richest bidder sets a number the others must approach, and Arrowhead benefits whether or not that bidder is the one it ultimately accepts.
The honest qualification on Arrowhead’s side mirrors the one on Lilly’s. A diversified giant that can walk away from any single opportunity is a buyer whose interest, while real, may not be urgent, and Arrowhead cannot simply assume Lilly will pursue it to the end. The leverage comes not from any certainty that Lilly will buy, but from the credible possibility that it could, which is enough to discipline the other suitors regardless of what Lilly ultimately does. As always in this series, the point is not that Arrowhead should hold out for Lilly, or for anyone. It is that a company holding a strong position, with a credible path to independence and more than one able suitor, negotiates from a position of command rather than need.
VIII. Conclusion: “Check”
Lilly is the suitor that can simply pay. It fits Arrowhead across obesity, neurodegeneration, and cardiometabolic disease; it buys from overwhelming strength rather than from the pressure of a cliff; it has deliberately become the industry’s most aggressive acquirer; and it can absorb a price, and a risk, that would give a more disciplined or more concentrated buyer pause. On the merits of resources alone, Lilly is the most formidable of the three suitors, because the one thing a price-taker cannot do is out-pay a giant, and Lilly is the giant.
The deeper significance of Lilly, though, is structural. Its entry is the “check” that forces the board to reorganize. The moment a buyer with Lilly’s resources is plausibly in the game, no other suitor can act as though the game were uncontested. Novartis can no longer wait on its comfortable timetable. The quiet bilateral negotiation that the first paper imagined gives way to a contested field in which every player must move with one eye on the others. That is what a “check” does. It does not end the game; it ends the freedom of everyone else to ignore the threat.
One player, though, has still not been heard from, and it is the one with the deepest claim of all to the science Arrowhead is built on, and the strongest temperamental reluctance to do anything about it. Lilly’s “check” forces a response from everyone on the board, including the most disciplined, most science-proud, most acquisition-averse suitor of the three. What happens when a company that prefers never to be forced is finally forced, when the only player who would rather license than buy discovers that licensing no longer protects it, is the subject of the final paper. The warning has sounded. The “check” has been given. The position that leaves the last player with no good move is what remains.
A Note on Supporting Independent Research
If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.
For individual investors and readers
Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.
For family offices, investment funds, hedge funds, and research platforms
This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.
There is no obligation and no expectation. This is purely a thank you for work that meant something to you.
Zelle: (847) 227-7909
Thank you for reading, and for being part of a community that takes this thesis seriously.
— Robert Toczycki | BioBoyScout
Important Risks, Disclosures, & Disclaimers
The author, Robert Toczycki (aka BioBoyScout), certifies that:
all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;
he was not compensated in any form for producing this white paper; and
he has not received and does not receive compensation from Arrowhead Pharmaceuticals.
This paper is provided for informational and analytical purposes only. It is a strategic thought experiment based entirely on publicly available information, including company acquisition histories, public strategic statements, earnings disclosures, and trade press reporting, as of the date of publication. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. It is not a prediction of any transaction, and the author has no knowledge of any actual deal discussions among any of the companies described. Scenarios involving how companies would behave are analytical interpretations grounded in documented past behavior, not statements of fact about any company’s intentions or any individual’s thinking. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper.
About the Author
BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.
Comments or questions: bioboyscout@gmail.com.
Copyright © 2026, BioBoyScout. All Rights Reserved.
